Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2020
CADTH recommends new treatment option for patients with plaque psoriasis
30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...
Posted by Michael Wonder on 01 Nov 2020
FDA approves Bronchitol for US market
2 November 2020 - Pharmaxis to manufacture product and export to USA. ...
Posted by Michael Wonder on 01 Nov 2020
BMS appeals final appraisal document for nivolumab for non-small cell lung cancer
30 October 2020 - The appeal will be heard on 1 December 2020. ...
Posted by Michael Wonder on 01 Nov 2020
MHRA grants HAE patients early access to BioCryst’s berotralstat in United Kingdom
30 October 2020 - BioCryst Pharmaceuticals today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency has granted ...
Posted by Michael Wonder on 01 Nov 2020
Novartis sickle cell medicine Adakveo approved in Europe to prevent recurrent vaso-occlusive crises
30 October 2020 - Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises available for ...
Posted by Michael Wonder on 01 Nov 2020
John Ivison: The math of saving lives — Canada's drug battle leaves patients caught in the middle
31 October 2020 - By cold mathematics, spending $1.3 billion to transform the lives of 3,700 Canadians might seem a ...
Posted by Michael Wonder on 01 Nov 2020
Schedule of Pharmaceutical Benefits - 1 November 2020
1 November 2020 - The November 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Nov 2020
New Zealand Pharmaceutical Schedule - 1 November 2020
1 November 2020 - The November 2020 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2020
European Medicines Agency accepts Biogen’s aducanumab marketing authorisation application for Alzheimer's disease
30 October 2020 - If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and ...
Posted by Michael Wonder on 31 Oct 2020
Gilead’s COVID-19 drug is mediocre. It will be a blockbuster anyway.
29 October 2020 - Gilead Sciences said Wednesday that remdesivir, which has been authorised for emergency use since the spring, brought ...
Posted by Michael Wonder on 31 Oct 2020
Extra transparency measures for COVID-19 vaccines and therapeutics
30 October 2020 - Today the EMA has implemented two further extra transparency measures for COVID-19 medicines, by publishing both ...
Posted by Michael Wonder on 30 Oct 2020
NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
30 October 2020 - All eligibility criteria must be met for liraglutide to be offered. ...
Posted by Michael Wonder on 30 Oct 2020
ICR welcomes NICE’s decision to reassess abiraterone acetate as first-line treatment for advanced prostate cancer
29 October 2020 - The Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider ...
Posted by Michael Wonder on 30 Oct 2020
Public Summary Documents - PBAC July 2020
30 October 2020 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2020 PBAC ...
Posted by Michael Wonder on 29 Oct 2020
PTAC recommends the reimbursement of osimertinib mesylate for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer
29 October 2020 - PTAC has acknowledged the high unmet clinical need and the high quality, randomised control trial evidence ...